Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment
MedComm · 2025-06 · 6 (6)
DOI: 10.1002/mco2.70193 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 15.05.2025. Verfasst von Meiling Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of Biomedical Nanomaterials and Devices Hunan University of Technology Zhuzhou China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Minimal residual disease (MRD) serves as a pivotal biomarker for the clinical diagnosis and subsequent treatment of cancer patients. In hematological malignancies, MRD pose an increasingly serious threat to the health of Chinese people. Accurate MRD detection is essential for assessing relapse risk and optimizing therapeutic strategies, yet current methods such as flow cytometry, polymerase chain reaction (PCR), and next‐generation sequencing (NGS) each have distinct limitations, and significant gaps remain in achieving optimal sensitivity and specificity of these technologies. This review provides a comprehensive analysis of MRD detection methods, high‐lighting their clinical implications, including their roles in treatment decision‐making, risk stratification, and patient outcomes. It discusses the strengths and weaknesses of existing techniques and explores emerging technologies that promise enhanced diagnostic precision. Key advancements such as integrating NGS with other methodologies and novel approaches like liquid biopsy and PCR are examined. The review underscores the academic and practical value of early and accurate MRD detection, emphasizing its impact on improving patient management and treatment outcomes. By addressing the limitations of current technologies and exploring future directions, this review aims to advance the field and support personalized medicine approaches to cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hunan Key Laboratory of Biomedical Nanomaterials and Devices Hunan University of Technology Zhuzhou China.
- Department of Cell Biology and Genetics School of Basic Medical Sciences Hengyang Medical School University of South China Hengyang China.
- Institute for Future Sciences University of South China Changsha China.
- National Health Commission Key Laboratory of Birth Defect Research and Prevention Changsha China.
- State Key Laboratory of Bioelectronics School of Biological Science and Medical Engineering Southeast University Nanjing China.
- Key Laboratory of Rare Pediatric Diseases Ministry of Education University of South China Hengyang China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Song, M., Pan, W., Yu, X., Ren, J., Tang, C., Chen, Z., Wang, Z., Deng, Y., He, N., Liu, H., & Li, S. (2025). Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. MedComm, 6(6). https://doi.org/10.1002/mco2.70193
Vancouver
Song M, Pan W, Yu X, Ren J, Tang C, Chen Z, et al. Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. MedComm. 2025;6(6). doi:10.1002/mco2.70193
BibTeX
@article{Song2025,
author = {Song, Meiling and Pan, Wenjing and Yu, Xinjie and Ren, Jie and Tang, Congli and Chen, Zhu and Wang, Zhe and Deng, Yan and He, Nongyue and Liu, Hongna and Li, Song},
title = {Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment},
journal = {MedComm},
year = {2025},
volume = {6},
number = {6},
doi = {10.1002/mco2.70193}
}
EUVIMED